ORDER GENIE HERE
Transcriptomics: the Final Frontier for Chronic Fatiguing Illnesses Metabolic testing is now available
Welcome “Genie’ (Genomic expression: Inflammation Explained
Yes, the test is now here. After ten years in concept and three years in development and validation, the application of transcriptomics to confirm hypometabolism (see below) is available. Based on the work of James Ryan, PhD, for the first time we can use differential gene expression to tell us about abnormalities in gene functioning in illnesses characterized by chronic fatigue. Understanding the gene expression lets us use targeted therapies based on our published, peer-reviewed work.
As you may guess by the name, hypometabolism indicates abnormally low metabolic activity. Finally, we have the definitive test that adds weight to both diagnosis and the sequential monitoring that shows the effects of therapy. Incredible. We don’t have to guess about illnesses without objective biomarkers, like fibromyalgia and Chronic Fatigue Syndrome (CFS). We will define CFS by transcriptomics and not by non-specific symptoms.
And we can show what chronic inflammatory response syndrome (CIRS) truly is in patients harmed by water-damaged buildings (WDB) and Post-Lyme Syndrome.
We can show when therapy is completed: the search for the “cure” word is upon us. We can confirm relapse should that tragically occur. We can show progress in the twelve steps of therapy.
Hypometabolism includes pathologic suppression of both ribosomal and nuclear-encoded mitochondrial genes. Actual mitochondrial genes still resident in mitochondria number 37; the other 1000 or so are in our own nuclear DNA. Hypometabolism shows us the dominant role of differential gene activation in pathogenesis and perpetuation of chronic fatiguing illnesses.
Treatment of hypometabolism with our published, peer-reviewed protocols shows sequential resolution of gene suppression/activation. For the first time we can now track the pathological basis of chronic fatigue and critical inflammatory elements throughout treatment.
Let the newest science train your thinking; conduct your diagnosis and treatment; and punch your ticket to salutary outcomes. This hypometabolism panel contains 175 reporter genes, covering a wide range of areas from mitochondrial ATP synthase to Toll like receptors to caspases and more.
THIS TEST IS CURRENTLY ONLY AVAILABLE TO IN THE UNITED STATES. INTERNATIONAL ORDERS WILL BE CANCELLED AND REFUNDED. Please note that the order does not include return shipping to the Lab. The purchaser will be required to pay to ship the samples back to the lab. Effective April 6, 2019 there will be a $25 restocking fee deducted from any returns